Federal Circuit Hints at the Scope of Government’s License Rights
What You Need to Know
Key takeaway #1
Under the Bayh-Dole Act, the government has a royalty-free license to inventions funded by federal grants.
Key takeaway #2
The Bayh-Dole Act does not include temporal limitations, so it may apply to inventive work performed before a funding agreement is executed or its effective date.
Client Alert | 3 min read | 02.21.24
The Federal Circuit’s decision in University of South Florida Board of Trustees v. United States, 22-2248 (Fed. Cir. Feb. 9, 2024) hints at the broad scope of the federal government’s license rights under the Bayh-Dole Act.
This case originates from a patent infringement dispute at the Court of Federal Claims pursuant to 28 U.S.C. § 1498(a). The University of South Florida (“USF”), the owner of a patent covering transgenic mice used in Alzheimer’s research, sued the federal government because a government contractor, with the government’s authorization and consent, had been producing and using transgenic mice covered by the patent. As a defense, the government argued that it had a license to the invention under the Bayh-Dole Act, because the invention was developed using government funding. The Court of Federal Claims sided with the government, finding no infringement.
On appeal, the Federal Circuit upheld the government’s license to the patented invention. The Federal Circuit found that research leading to the invention was “in the performance of work under a funding agreement”—even though this research was conducted months before the effective date of the funding agreement. Therefore, it is a “subject invention” for which the government obtained a license.
Funding for the research leading to the patented invention came from an NIH grant to the Mayo Clinic, but part of that research—indeed the first reduction to practice of the patented invention—was conducted at USF. As a result of this arrangement, NIH policies implementing the Bayh-Dole Act required Mayo and USF to enter into a subcontract with each other in order for grant money received by Mayo to be paid to USF for conducting the research. Mayo and USF only executed this contract months after USF scientists had completed the first reduction to practice of the patented invention.
The Federal Circuit found that the Bayh-Dole Act does not require a funding agreement to predate work done in furtherance of an invention. To the contrary, the Federal Circuit found the Bayh-Dole Act’s language is broad, providing for “payment for work already performed before the subcontract is executed or its effective date.” Because USF entered into a funding agreement with Mayo and accepted NIH funding from Mayo for the research done before the funding agreement was inked, the Federal Circuit found the Bayh-Dole Act applied to that research.
The Federal Circuit explained that the record strongly supported its conclusion, because the fact pattern illustrated in this case—a subcontract not executed until after the grant is awarded, “yet the grant-covered work proceeds without waiting for the inking of a subcontract”—is a common one. The Court reasoned that this fact pattern allows for the advancement of useful knowledge without waiting for the formalities of a grant award to be finalized.
This decision comes at a time when the Executive Branch has released draft guidance on factors, including price and other terms, that an agency may consider when deciding whether to exercise march-in rights. The draft guidance is being presented by the White House as part of actions intended to promote the affordability of taxpayer-funded drugs and other inventions, but the proposed policies have raised concerns about the impact upon innovation.
Accordingly, innovators and licensees may wish to keep in mind the potential federal governmental rights to inventions as they seek funding, draft licensing agreements, and conduct due diligence on research inputs—both past and present, and how they intend to price products or methods.
Contacts
Insights
Client Alert | 4 min read | 03.25.26
NAIC Intensifies AI Regulatory Focus: What Health Insurance Payors Need to Know
The National Association of Insurance Commissioners (NAIC) is intensifying its oversight of how insurers use AI — and the pace of regulatory activity shows no signs of slowing. Over the past several months, the NAIC has published a formal Issue Brief staking out its position on federal AI legislation, launched a multistate AI Evaluation Tool pilot aimed at examining insurers’ AI governance programs, and continued to expand adoption of its AI Model Bulletin across state lines. These developments continue a trend towards enhancing regulation; the NAIC adopted AI Principles in 2020 and a Model Bulletin in 2023 clarifying that existing insurance laws apply to AI systems and establishing expectations for governance, documentation, testing, and third-party oversight. That Model Bulletin has now been adopted in approximately 24 states.
Client Alert | 11 min read | 03.25.26
White House National AI Policy Framework Calls for Preempting State Laws, Protecting Children
Client Alert | 3 min read | 03.24.26
California Considering A Massive Expansion of Its Antitrust Laws
Client Alert | 2 min read | 03.23.26


